The chemical-transformation products of 1,6-dibromo-1,6-dideoxygalactitol and 1,2:5,6-dianhydrogalactitol in aqueous solution

After hydrolysis of 1,6-dibromo-1,6-dideoxygalactitol (1) and 1,2:5,6-dianhydrogalactitol (2), 11 compounds were isolated, three of them as tritylated derivatives. Their structures were established on the basis of chemical evidence and, for four compounds, by X-ray diffraction. The main product of the hydrolysis of 1 was 3,6-anhydro-1-bromo-1-deoxy-dl-galactitol; the end-products of the hydrolysis of 2 were 1,5-anhydro-dl-galactitol, 2,5-anhydro-dl-altritol, and galactitol.     

Reaction of methyl β-d-glycero-l-manno-heptopyranoside with cyclohexanone: Synthesis of the 4- and 6-methyl ethers of d-glycero-l-manno-heptitol

Acid-catalysed condensation of methyl β-d-glycero-l-manno-heptopyranoside with cyclohexanone yielded an approximately 3:1 mixture of the 2,3:6,7- and 2,3:4,7-di-O-cyclohexylideneheptosides (1 and 2), which could be separated either as their benzoates (3 and 4) or as their methyl ethers (5 and 6). The latter compounds afforded the 4- and 6-methyl ethers (7 and 8) of d-glycero-l-manno-heptitol.     

Rare and new cumaceans (Crustacea,Peracarida) from?the southern margin of the Cap Ferret Canyon (Bay of Biscay)

A new cumacean genus and species, Ithyleucon sorbei gen. et sp. n., was described from material collected in the southern margin of the Cap Ferret Canyon (Bay of Biscay, NE Atlantic). Although the new genus resembles Pseudoleucon Zimmer, 1903, in terms of the general aspect of the carapace and the pseudo-rostrum position, it shows important differences in the uropod structure and in the size of the antenna 1 accessory flagellum. In addition, some comments regarding the morphology of certain rare species (Mesolamprops denticulatus Ledoyer, 1983, Hemilamprops normani Bonnier, 1896 and Schizocuma spino-culatum (Jones, 1984)) are also provided.     

Inhibiting effect of (sarcosine-1-isoleucine-8)-angiotensin II in anesthesized rats

The peptidic sequence (Sarcosine-1-Isoleucine-8)-Angiotensin II has been demonstrated to be an in vitro specific and competitive antagonist of the Angiotensin II action. The present results show it to be a competitive antagonist also in vivo since pA2 values are similar, always reaches a 100% response on increasing the Angiotensin II dose, and when relating log (DR-1) and log dose of agonist, the slope is very near to one (0.925).